Revvity (NYSE:RVTY) Given “Peer Perform” Rating at Wolfe Research

Revvity (NYSE:RVTY)‘s stock had its “peer perform” rating reaffirmed by Wolfe Research in a report released on Tuesday,Benzinga reports.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings cut Revvity from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 13th. The Goldman Sachs Group lowered their target price on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. TD Cowen upped their target price on Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Robert W. Baird set a $117.00 target price on Revvity in a report on Wednesday, May 6th. Finally, Barclays upped their target price on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Revvity has an average rating of “Hold” and a consensus target price of $107.73.

Revvity Stock Performance

NYSE:RVTY opened at $100.44 on Tuesday. The stock has a fifty day moving average price of $92.32 and a 200-day moving average price of $97.31. The company has a market cap of $11.21 billion, a price-to-earnings ratio of 48.06, a PEG ratio of 2.25 and a beta of 1.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $118.30.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same period in the prior year, the company posted $1.01 EPS. The company’s revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, equities analysts anticipate that Revvity will post 5.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Revvity

Several large investors have recently added to or reduced their stakes in RVTY. AQR Capital Management LLC grew its stake in Revvity by 5.2% during the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock worth $883,000 after purchasing an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Revvity by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock worth $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC grew its stake in Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. grew its stake in Revvity by 45.5% during the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after purchasing an additional 189,871 shares during the period. Finally, Focus Partners Wealth grew its stake in Revvity by 13.0% during the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.